The effects of isoproterenol on the cardiac conduction system: Site- specific dose dependence

Sergio F. Cossú, Steven A. Rothman, I. Lisa Chmielewski, Henry H. Hsia, R. Lee Vogel, John Miller, Alfred E. Buxton

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Introduction: Isoproterenol is used to assess and facilitate AV nodal conduction, and thus potentiate the induction of supraventricular arrhythmias. It is commonly administered in increasing doses until a predetermined decrease in sinus cycle length, usually 20% to 30%, occurs. This regimen may result in undesirable side effects. We have observed that effects of isoproterenol on the AV node may occur prior to achieving the target sinus cycle length. The purpose of this study was to determine whether the sinus and AV nodes have equal sensitivity to isoproterenol. Methods and Results: Thirty-eight consecutive patients, who underwent electrophysiologic evaluation for a variety of indications, were given incremental doses of isoproterenol at 0.007, 0.014, 0.021, and 0.028 μg/kg per minute. Sinus cycle length and AV node function were assessed at baseline and after 5 minutes at each dose. The percent change from baseline in AV node function was compared with the change in sinus cycle length at each dose interval. Significantly greater decreases were observed in the anterograde and retrograde AV nodal Wenckebach cycle length (P <0.0001) than in the sinus cycle length at the lowest isoproterenol dose (0.007 μg/kg per min). These differences were not apparent at higher doses. A sustained supraventricular tachycardia was inducible in 15 of 38 patients in the presence of isoproterenol, of which 40% occurred at the lowest dose. Conclusions: The AV node is more sensitive than the sinus node to the effects of isoproterenol. Lower doses of isoproterenol than those commonly used may often facilitate the induction of a supraventricular tachyarrhythmia, thus reducing side effects.

Original languageEnglish (US)
Pages (from-to)847-853
Number of pages7
JournalJournal of Cardiovascular Electrophysiology
Volume8
Issue number8
StatePublished - 1997
Externally publishedYes

Fingerprint

Isoproterenol
Atrioventricular Node
Sinoatrial Node
Supraventricular Tachycardia
Tachycardia
Cardiac Arrhythmias

Keywords

  • Atrioventricular conduction
  • Electrophysiologic study
  • Isoproterenol
  • Refractoriness
  • Supraventricular tachycardia

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Physiology

Cite this

Cossú, S. F., Rothman, S. A., Chmielewski, I. L., Hsia, H. H., Vogel, R. L., Miller, J., & Buxton, A. E. (1997). The effects of isoproterenol on the cardiac conduction system: Site- specific dose dependence. Journal of Cardiovascular Electrophysiology, 8(8), 847-853.

The effects of isoproterenol on the cardiac conduction system : Site- specific dose dependence. / Cossú, Sergio F.; Rothman, Steven A.; Chmielewski, I. Lisa; Hsia, Henry H.; Vogel, R. Lee; Miller, John; Buxton, Alfred E.

In: Journal of Cardiovascular Electrophysiology, Vol. 8, No. 8, 1997, p. 847-853.

Research output: Contribution to journalArticle

Cossú, SF, Rothman, SA, Chmielewski, IL, Hsia, HH, Vogel, RL, Miller, J & Buxton, AE 1997, 'The effects of isoproterenol on the cardiac conduction system: Site- specific dose dependence', Journal of Cardiovascular Electrophysiology, vol. 8, no. 8, pp. 847-853.
Cossú, Sergio F. ; Rothman, Steven A. ; Chmielewski, I. Lisa ; Hsia, Henry H. ; Vogel, R. Lee ; Miller, John ; Buxton, Alfred E. / The effects of isoproterenol on the cardiac conduction system : Site- specific dose dependence. In: Journal of Cardiovascular Electrophysiology. 1997 ; Vol. 8, No. 8. pp. 847-853.
@article{d4914995fc714163a3c966285e52a802,
title = "The effects of isoproterenol on the cardiac conduction system: Site- specific dose dependence",
abstract = "Introduction: Isoproterenol is used to assess and facilitate AV nodal conduction, and thus potentiate the induction of supraventricular arrhythmias. It is commonly administered in increasing doses until a predetermined decrease in sinus cycle length, usually 20{\%} to 30{\%}, occurs. This regimen may result in undesirable side effects. We have observed that effects of isoproterenol on the AV node may occur prior to achieving the target sinus cycle length. The purpose of this study was to determine whether the sinus and AV nodes have equal sensitivity to isoproterenol. Methods and Results: Thirty-eight consecutive patients, who underwent electrophysiologic evaluation for a variety of indications, were given incremental doses of isoproterenol at 0.007, 0.014, 0.021, and 0.028 μg/kg per minute. Sinus cycle length and AV node function were assessed at baseline and after 5 minutes at each dose. The percent change from baseline in AV node function was compared with the change in sinus cycle length at each dose interval. Significantly greater decreases were observed in the anterograde and retrograde AV nodal Wenckebach cycle length (P <0.0001) than in the sinus cycle length at the lowest isoproterenol dose (0.007 μg/kg per min). These differences were not apparent at higher doses. A sustained supraventricular tachycardia was inducible in 15 of 38 patients in the presence of isoproterenol, of which 40{\%} occurred at the lowest dose. Conclusions: The AV node is more sensitive than the sinus node to the effects of isoproterenol. Lower doses of isoproterenol than those commonly used may often facilitate the induction of a supraventricular tachyarrhythmia, thus reducing side effects.",
keywords = "Atrioventricular conduction, Electrophysiologic study, Isoproterenol, Refractoriness, Supraventricular tachycardia",
author = "Coss{\'u}, {Sergio F.} and Rothman, {Steven A.} and Chmielewski, {I. Lisa} and Hsia, {Henry H.} and Vogel, {R. Lee} and John Miller and Buxton, {Alfred E.}",
year = "1997",
language = "English (US)",
volume = "8",
pages = "847--853",
journal = "Journal of Cardiovascular Electrophysiology",
issn = "1045-3873",
publisher = "Wiley-Blackwell",
number = "8",

}

TY - JOUR

T1 - The effects of isoproterenol on the cardiac conduction system

T2 - Site- specific dose dependence

AU - Cossú, Sergio F.

AU - Rothman, Steven A.

AU - Chmielewski, I. Lisa

AU - Hsia, Henry H.

AU - Vogel, R. Lee

AU - Miller, John

AU - Buxton, Alfred E.

PY - 1997

Y1 - 1997

N2 - Introduction: Isoproterenol is used to assess and facilitate AV nodal conduction, and thus potentiate the induction of supraventricular arrhythmias. It is commonly administered in increasing doses until a predetermined decrease in sinus cycle length, usually 20% to 30%, occurs. This regimen may result in undesirable side effects. We have observed that effects of isoproterenol on the AV node may occur prior to achieving the target sinus cycle length. The purpose of this study was to determine whether the sinus and AV nodes have equal sensitivity to isoproterenol. Methods and Results: Thirty-eight consecutive patients, who underwent electrophysiologic evaluation for a variety of indications, were given incremental doses of isoproterenol at 0.007, 0.014, 0.021, and 0.028 μg/kg per minute. Sinus cycle length and AV node function were assessed at baseline and after 5 minutes at each dose. The percent change from baseline in AV node function was compared with the change in sinus cycle length at each dose interval. Significantly greater decreases were observed in the anterograde and retrograde AV nodal Wenckebach cycle length (P <0.0001) than in the sinus cycle length at the lowest isoproterenol dose (0.007 μg/kg per min). These differences were not apparent at higher doses. A sustained supraventricular tachycardia was inducible in 15 of 38 patients in the presence of isoproterenol, of which 40% occurred at the lowest dose. Conclusions: The AV node is more sensitive than the sinus node to the effects of isoproterenol. Lower doses of isoproterenol than those commonly used may often facilitate the induction of a supraventricular tachyarrhythmia, thus reducing side effects.

AB - Introduction: Isoproterenol is used to assess and facilitate AV nodal conduction, and thus potentiate the induction of supraventricular arrhythmias. It is commonly administered in increasing doses until a predetermined decrease in sinus cycle length, usually 20% to 30%, occurs. This regimen may result in undesirable side effects. We have observed that effects of isoproterenol on the AV node may occur prior to achieving the target sinus cycle length. The purpose of this study was to determine whether the sinus and AV nodes have equal sensitivity to isoproterenol. Methods and Results: Thirty-eight consecutive patients, who underwent electrophysiologic evaluation for a variety of indications, were given incremental doses of isoproterenol at 0.007, 0.014, 0.021, and 0.028 μg/kg per minute. Sinus cycle length and AV node function were assessed at baseline and after 5 minutes at each dose. The percent change from baseline in AV node function was compared with the change in sinus cycle length at each dose interval. Significantly greater decreases were observed in the anterograde and retrograde AV nodal Wenckebach cycle length (P <0.0001) than in the sinus cycle length at the lowest isoproterenol dose (0.007 μg/kg per min). These differences were not apparent at higher doses. A sustained supraventricular tachycardia was inducible in 15 of 38 patients in the presence of isoproterenol, of which 40% occurred at the lowest dose. Conclusions: The AV node is more sensitive than the sinus node to the effects of isoproterenol. Lower doses of isoproterenol than those commonly used may often facilitate the induction of a supraventricular tachyarrhythmia, thus reducing side effects.

KW - Atrioventricular conduction

KW - Electrophysiologic study

KW - Isoproterenol

KW - Refractoriness

KW - Supraventricular tachycardia

UR - http://www.scopus.com/inward/record.url?scp=0030756091&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030756091&partnerID=8YFLogxK

M3 - Article

C2 - 9261710

AN - SCOPUS:0030756091

VL - 8

SP - 847

EP - 853

JO - Journal of Cardiovascular Electrophysiology

JF - Journal of Cardiovascular Electrophysiology

SN - 1045-3873

IS - 8

ER -